BRIEF—3T Biosciences launches with Series A led by Westlake Village

California, USA-based 3T Biosciences (3T), an immunotherapy company changing the future of treatment for solid tumors and other immune-mediated diseases, today announced its launch from stealth backed by $40 million Series A financing led by Westlake Village BioPartners with participation from Lightspeed Venture Partners.

As part of its launch, 3T announced it has exclusively in-licensed from Stanford University a precise antibody-based peptide-HLA therapeutic discovery platform and development-stage MAGE-A3 T-cell receptor (TCR)-T assets to rapidly expand 3T’s therapeutic portfolio.

Proceeds from the financing will be used to help accelerate 3T from a research-focused company to a clinical-stage company by bringing novel targets into clinical development.

Executive appointment

The company also announced the appointment of Dr Stefan Scherer, as president and chief executive, and Christopher (Chris) DeRespino, as chief business officer.

In addition, the company named its board of directors, chaired by Dr Sean Harper, a co-founding managing director at Westlake, and its scientific advisory board, led by K Christopher Garcia, one of the world’s foremost experts in TCRs and scientific co-founder.